Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 9/20 | 0.59 |
| ▸ | CASP2 | P42575 | 1/20 | 0.53 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.53 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.52 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.50 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.50 |
| ▸ | NAAA | Q02083 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.49 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.49 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.49 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.49 |
| ▸ | RRM1 | P23921 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9868236 | 1.00 | EPHX1 (0.59) | EPHX1CASP2PLA2G2ADPP7ZDHHC20 | |
| SCHEMBL2321087 | 0.98 | EPHX1 (0.56) | EPHX1CASP2PLA2G2ADPP7ZDHHC20 | |
| SCHEMBL9868852 | 0.91 | EPHX1 (0.50) | EPHX1PLA2G2ADPP7EPHX2PLA2G4A | |
| SCHEMBL9060648 | 0.89 | EPHX1 (0.73) | EPHX1CASP2PLA2G2ADPP7ZDHHC20 | |
| SCHEMBL14656966 | 0.89 | EPHX1 (0.73) | EPHX1CASP2PLA2G2ADPP7ZDHHC20 | |
| SCHEMBL6857292 | 0.89 | EPHX1 (0.73) | EPHX1CASP2PLA2G2ADPP7ZDHHC20 | |
| SCHEMBL12203408 | 0.89 | EPHX1 (0.73) | EPHX1CASP2PLA2G2ADPP7ZDHHC20 | |
| SCHEMBL7642286 | 0.89 | EPHX1 (0.73) | EPHX1CASP2PLA2G2ADPP7ZDHHC20 | |
| SCHEMBL6859201 | 0.89 | EPHX1 (0.73) | EPHX1CASP2PLA2G2ADPP7ZDHHC20 | |
| SCHEMBL6854878 | 0.89 | EPHX1 (0.73) | EPHX1CASP2PLA2G2ADPP7ZDHHC20 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2914575-B1 | PLASMINOGEN ACTIVATOR-1 INHIBITORS AND METHODS OF USE THEREOF | UNIV MICHIGAN REGENTS (US) | 2020-10-14 | — | — | EP | disclosed |
| US-20170291893-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF | EASTERN MICHIGAN UNIVERSITY | 2017-10-12 | — | — | US | disclosed |
| US-9718760-B2 | Plasminogen activator inhibitor-1 inhibitors and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-08-01 | — | — | US | disclosed |
| US-20150315178-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2015-11-05 | — | — | US | disclosed |
| WO-2014070983-A1 | PLASMINOGEN ACTIVATOR-1 INHIBITORS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-05-08 | — | — | WO | disclosed |
| US-5051517-A | Reacting a chloroformidine hydrochloride with an oxamohydrazide, forming bonds between carbon and nitrogen and cyclization | BAYER AKTIENGESELLSCHAFT (DE) | 1991-09-24 | — | — | US | disclosed |
| EP-0126326-B1 | PROCESS FOR PREPARING 1,2,4-TRIAZOLE-3-CARBOXAMIDES | UBE INDUSTRIES, LTD. (JP) | 1987-08-05 | — | — | EP | disclosed |
| US-4578479-A | Process for preparing 1,2,4-triazole-3-carboxamides | UBE INDUSTRIES, LTD. (JP) | 1986-03-25 | — | — | US | disclosed |
| EP-0126326-A1 | Process for preparing 1,2,4-triazole-3-carboxamides | UBE INDUSTRIES, LTD. (JP) | 1984-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170291893-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF | SERPINE1, PLAT, SERPINC1 | EPHX1 353/4885CASP2 1157/4885PLA2G2A 450/4885 |
| US-20150315178-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF | SERPINE1, PLAT, SERPINC1 | EPHX1 353/4885CASP2 1157/4885PLA2G2A 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.